查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1718315

抗風濕藥物市場按藥物類別、給藥途徑、類型、疾病類型和分銷管道分類－2025-2030 年全球預測

Anti-Rheumatics Market by Drug Class, Route Of Administration, Type, Disease Type, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

抗風濕藥物市場預計2023年將達到915.4億美元，2024年將達到965.6億美元，到2030年將達到1,347.7億美元，複合年成長率為5.68%。

主要市場統計數據
基準年2023年 915.4億美元
預計2024年 965.6億美元
預測年份 2030 1347.7億美元
複合年成長率（%） 5.68%

全球抗風濕藥物市場正在經歷顯著變革，需要深入了解不斷發展的治療模式。近年來，相關人員見證了治療方法的空前進步，推動了各個領域穩定而有希望的成長。本報告提供了深入的分析，不僅反映了當前的行業指標，還預測了未來的挑戰和機會。不斷成長的患者需求加上創新的研究和開發正在推動市場相關人員重新評估傳統治療策略並採用新的治療方法。醫療保健環境的動態特性促進了合作和競爭的精神，從而顯著改善了患者的治療效果並增強了產品平臺。此外，全球政策和監管改革也在不斷發展，簡化了加速產品核可和增強市場信心的途徑。該研究利用強大的數據分析和先進的數位工具，提供了對決策者和行業專業人士至關重要的全面觀點。本簡報是了解風濕病市場複雜性的入門讀物，也是深入研究關鍵產業趨勢和競爭策略的基礎。

改變抗風濕藥物市場

近年來，抗風濕藥物市場發生了轉變，將自己定位在醫療創新和患者照護的前沿。該行業已經出現了大量先進的研究方法，從而可以開發標靶治療和個性化的治療方法。這些創新是由生物技術的進步和對風濕病病理病理學的更深入理解所推動的。法律規範也發生了重大變化，一些地區的主管部門加快了核准流程，使突破性治療方法能夠更快地進入市場。合資企業和策略夥伴關係增強了研究和開發，使得針對特定發炎途徑的新型藥物得到廣泛應用。此外，人們特別關注數位健康和​​數據分析的應用，這可以改善診斷和病患監測，並最終改善治療結果。隨著患者尋求更有效、更安全的替代醫療方法，該行業迅速做出反應，將最尖端科技融入傳統醫療模式。這種適應性方法不僅使其產品多樣化，而且增強了其市場競爭力。發展趨勢表明，技術與藥物開發的融合將繼續成為抗風濕藥物市場成功的關鍵決定因素。

風濕病市場的詳細細分分析

詳細的市場細分分析揭示了抗風濕藥物市場的複雜性，突顯了推動患者照護和商業性成功的多維因素。市場按藥物類別細分，包括對皮質類固醇、緩解疾病的抗風濕藥物、非類固醇消炎劑和尿酸藥物的詳細研究。在緩解疾病的抗風濕藥物領域中特別值得注意的是它細分為生物製劑 DMARD、常規 DMARD 和標靶合成 DMARD。基於 B 細胞抑制劑、白細胞介素抑制劑、T 細胞共刺激調節劑和腫瘤壞死因子 (TNF) 抑制劑進一步探討生物 DMARD 的每個部分，以闡明其具體的作用機制和治療細微差別。此外，該分析還擴展到給藥途徑，了解注射、口服和局部製劑的動力學，有助於將患者偏好與臨床療效相匹配。按產品類型細分，區分非處方藥和處方藥，以符合法規要求和市場進入。疾病類型透過考慮僵直性脊椎炎、黏液囊炎、痛風、幼年特發性關節炎、骨關節炎、乾癬性關節炎類風濕性關節炎、修格蘭氏症候群、系統性紅斑狼瘡、全身性紅斑性狼瘡硬皮症/硬皮症和肌腱炎等疾病進一步細分市場研究。最後一層細分考慮分銷管道，重點關注醫院藥房、線上藥房和零售藥房，這些管道在這些治療的可用性和商業化中發揮關鍵作用。這種全面的細分提供了市場的詳細全景，並為相關人員提供了未來商業機會所在的策略見解。

目錄

第1章 引言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章 市場洞察

  • 市場動態
    • 驅動程式
      • 風濕病患病率不斷上升
      • 提高對類風濕性關節炎早期篩檢和治療的認知
      • 專注於精準醫療和個人化醫療
    • 限制因素
      • 抗風濕藥物的副作用與安全問題
    • 機會
      • 政府對風濕病研究與發展的計劃與支持
      • 具有成本效益的生物相似藥的關鍵開發和分銷
    • 任務
      • 複雜的藥物研發與核准流程
  • 市場區隔分析
    • 藥物類別：非類固醇消炎劑因其可用性、可負擔性和有效的疼痛管理而日益普及
    • 給藥途徑：口服藥物製劑的進步可提高生物有效性並最大程度減少副作用
    • 類型：嚴重和慢性風濕病的治療首選處方藥
    • 疾病類型：類風濕性關節炎個人化醫療的進展，以最佳化療效並最大限度地減少副作用
    • 分銷管道：擴大抗風濕藥物的網路藥局分銷
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

第6章抗風濕藥物市場（依藥物類別）

  • 介紹
  • 皮質類固醇
  • 緩解疾病的抗風濕藥物
    • 生物藥物
      • B細胞抑制劑
      • 白細胞介素抑制劑
      • T細胞共刺激調節劑
      • 腫瘤壞死因子（TNF）抑制劑
    • 傳統 DMARD 藥物
    • 標靶合成DMARD
  • 非類固醇消炎劑
  • 尿酸藥物

第7章抗風濕藥物市場（依給藥途徑）

  • 介紹
  • 注射
  • 口服
  • 局部的

第8章抗風濕藥物市場（按類型）

  • 介紹
  • 非處方藥
  • 處方藥

第9章抗風濕藥物市場（依疾病型態）

  • 介紹
  • 僵直性脊椎炎
  • 黏液囊炎
  • 痛風
  • 幼年特發性關節炎
  • 骨關節炎
  • 骨質疏鬆症
  • 多肌痛
  • 乾癬性關節炎
  • 類風濕性關節炎
  • 修格蘭氏症候群
  • 全身性紅斑性狼瘡
  • 系統性硬皮症
  • 肌腱炎

第10章抗風濕藥物市場（依通路）

  • 介紹
  • 醫院藥房
  • 網路藥局
  • 零售藥局

第 11 章：美洲抗風濕藥物市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

12.亞太抗風濕藥物市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

13.歐洲、中東和非洲抗風濕藥物市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023年市場佔有率分析
  • 2023年FPNV定位矩陣
  • 競爭情境分析
  • 戰略分析與建議

公司名單

  • AbbVie Inc.
  • Alvotech
  • Amgen Inc.
  • ANI Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • CH Boehringer Sohn AG & Co. KG
  • DeepCure
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Fresenius Kabi AG
  • Galapagos NV
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • ILTOO Pharma SAS
  • Johnson & Johnson Services Inc.
  • medac GmbH
  • Merck & Co., Inc.
  • Novartis AG
  • Otter Pharmaceuticals, LLC by Assertio Holdings, Inc.
  • Pfizer, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • UCB SA
  • Vertex Pharmaceuticals Incorporated
Product Code: MRR-1A1A064C0147

The Anti-Rheumatics Market was valued at USD 91.54 billion in 2023 and is projected to grow to USD 96.56 billion in 2024, with a CAGR of 5.68%, reaching USD 134.77 billion by 2030.

KEY MARKET STATISTICS
Base Year [2023] USD 91.54 billion
Estimated Year [2024] USD 96.56 billion
Forecast Year [2030] USD 134.77 billion
CAGR (%) 5.68%

The global market for anti-rheumatics is undergoing an era of notable change that calls for a deep understanding of the evolving therapeutic landscape. In recent years, stakeholders have observed unprecedented advancements in treatment modalities, driving a steady and promising growth in various segments. This report introduces a detailed analysis that not only reflects current industry metrics but also anticipates future challenges and opportunities. Over time, increasing patient demand paired with innovative research and development has encouraged market players to reevaluate conventional treatment strategies and embrace novel therapeutic approaches. The dynamic nature of the healthcare environment has fostered a spirit of collaboration and competition, leading to significant improvements in patient outcomes and enhanced product pipelines. Furthermore, evolving global policies and regulatory reforms have streamlined pathways for faster product approvals and heightened market confidence. Leveraging robust data analytics and advanced digital tools, the study presents a comprehensive view that is essential for decision-makers and industry experts. This briefing serves as a primer to understand the complexities of the anti-rheumatics market, setting the stage for a detailed exploration of key industry trends and competitive strategies.

Transformative Shifts in the Anti-Rheumatics Market Landscape

Recent years have witnessed transformative shifts that have reshaped the anti-rheumatics market, positioning it at the frontier of medical innovation and patient care. The industry has experienced a surge in advanced research methodologies, enabling the development of targeted treatments and personalized therapies. These innovations have been driven by improvements in biotechnology and a deeper understanding of the pathophysiology of rheumatic diseases. A significant shift has been observed in the regulatory framework where authorities across several regions have expedited the approval processes, resulting in quicker market access for groundbreaking therapies. Collaborative ventures and strategic partnerships have bolstered research and development, leading to a proliferation of novel agents that target specific inflammatory pathways. Additionally, there has been a pronounced focus on embracing digital health and data analytics, which has improved diagnostics and patient monitoring, ultimately enhancing therapeutic outcomes. As patients demand more effective and safer alternatives, the industry has responded rapidly by integrating state-of-the-art technologies with traditional healthcare models. This adaptive approach has not only diversified the product offerings but has also strengthened market competitiveness. Emerging trends indicate that the convergence of technology with pharmaceutical development will continue to be a critical determinant of success in the anti-rheumatics market.

In-Depth Segmentation Insights Across the Anti-Rheumatics Market

A detailed segmentation analysis reveals the intricacies of the anti-rheumatics market and underscores the multi-dimensional factors driving patient care and commercial success. The market is categorized based on drug class, which includes an in-depth study of Corticosteroids, Disease Modifying Anti-rheumatics Drugs, Nonsteroidal Anti-inflammatory Drugs, and Uric Acid Drugs. Particularly noteworthy within the Disease Modifying Anti-rheumatics Drugs segment is the subdivision into Biologic DMARDs, Conventional DMARDs, and Targeted Synthetic DMARDs. Each segment within the Biologic DMARDs is further examined based on B-cell Inhibitors, Interleukin Inhibitors, T-cell Co-stimulation Modulators, and Tumor Necrosis Factor (TNF) Inhibitors, offering clarity on specific mechanisms of action and therapeutic nuances. Additionally, the analysis extends to the route of administration, capturing the dynamics of Injectable, Oral, and Topical formulations, which serve to match patient preference with clinical effectiveness. Segmentation based on product type distinguishes Over-the-Counter from Prescription-Based Drugs, thereby aligning regulatory requirements with market access. Disease type further refines the market study by considering conditions including Ankylosing Spondylitis, Bursitis, Gout, Juvenile Idiopathic Arthritis, Osteoarthritis, Osteoporosis, Polymyalgia Rheumatica, Psoriatic Arthritis, Rheumatoid Arthritis, Sjogren's Syndrome, Systemic Lupus Erythematosus, Systemic Sclerosis/Scleroderma, and Tendinitis. The final layer of segmentation examines distribution channels, highlighting Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies, which play a critical role in the accessibility and commercialization of these therapies. This comprehensive segmentation captures the detailed panorama of the market, offering stakeholders strategic insights into where future opportunities lie.

Based on Drug Class, market is studied across Corticosteroids, Disease Modifying Anti-rheumatics Drugs, Nonsteroidal Anti-inflammatory Drugs, and Uric Acid Drugs. The Disease Modifying Anti-rheumatics Drugs is further studied across Biologic DMARDs, Conventional DMARDs, and Targeted Synthetic DMARDs. The Biologic DMARDs is further studied across B-cell Inhibitors, Interleukin Inhibitors, T-cell Co-stimulation Modulators, and Tumor Necrosis Factor (TNF) Inhibitors.

Based on Route Of Administration, market is studied across Injectable, Oral, and Topical.

Based on Type, market is studied across Over-the-Counter Drugs and Prescription-Based Drugs.

Based on Disease Type, market is studied across Ankylosing Spondylitis, Bursitis, Gout, Juvenile Idiopathic Arthritis, Osteoarthritis, Osteoporosis, Polymyalgia Rheumatica, Psoriatic Arthritis, Rheumatoid Arthritis, Sjogren's Syndrome, Systemic Lupus Erythematosus, Systemic Sclerosis/Scleroderma, and Tendinitis.

Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.

Key Regional Insights: Navigating Global Opportunities in Anti-Rheumatics

Regional dynamics play a pivotal role in shaping the future trajectory of the anti-rheumatics market, and a nuanced understanding of geographical trends is essential. In the Americas, robust healthcare infrastructure and proactive policy measures have propelled the adoption of advanced therapies. The region presents lucrative opportunities anchored by high awareness, substantial investment in research, and progressive regulatory frameworks. Europe, Middle East & Africa is witnessing significant transformations with a focus on integrating traditional treatment models with novel therapeutic approaches. Stakeholders in this diverse region are increasingly examining the balance between cost-effectiveness and scientific innovation, paving the way for breakthrough approvals and enhanced patient outcomes. The Asia-Pacific region stands out due to its dynamic economic growth and rising middle-class populations that are driving an increased demand for quality healthcare services. Rapid urbanization, coupled with government initiatives to enhance healthcare access, has created a fertile ground for market expansion. By evaluating these regional insights, industry leaders can better strategize product positioning and market penetration, taking into account local regulatory landscapes, cultural nuances, and economic factors that influence patient care and adoption rates.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Comprehensive Analysis of Leading Companies in the Anti-Rheumatics Sector

The competitive landscape within the anti-rheumatics market is characterized by the presence of several key companies that are spearheading innovation and market expansion. Prominent entities such as AbbVie Inc., Alvotech, Amgen Inc., ANI Pharmaceuticals, Inc., and AstraZeneca PLC are at the forefront of developing and commercializing advanced therapies. Esteemed organizations like Bayer AG, Biogen Inc., Bristol-Myers Squibb Company, and C. H. Boehringer Sohn AG & Co. KG have consistently demonstrated excellence in clinical research and development. Emerging innovators including DeepCure and Eisai Co., Ltd. are also making significant inroads with specialized treatment offerings. Industry giants like Eli Lilly and Company, F. Hoffmann-La Roche Ltd., and Fresenius Kabi AG continue to leverage extensive research networks to drive product innovation. In addition, organizations such as Galapagos NV, Gilead Sciences, Inc., GlaxoSmithKline PLC, and ILTOO Pharma SAS provide crucial insights into market strategies and emerging trends. Well-established names including Johnson & Johnson Services Inc., medac GmbH, Merck & Co., Inc., and Novartis AG underscore the market's competitive intensity. Not to be overlooked are companies like Otter Pharmaceuticals, LLC by Assertio Holdings, Inc., Pfizer, Inc., Regeneron Pharmaceuticals, Inc., Sanofi SA, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., UCB S.A., and Vertex Pharmaceuticals Incorporated, whose collaborative efforts continue to redefine therapeutic standards in the field. Their strategic initiatives not only drive competitive advancements but also significantly impact the overall market dynamics.

The report delves into recent significant developments in the Anti-Rheumatics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Alvotech, Amgen Inc., ANI Pharmaceuticals, Inc., AstraZeneca PLC, Bayer AG, Biogen Inc., Bristol-Myers Squibb Company, C. H. Boehringer Sohn AG & Co. KG, DeepCure, Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Fresenius Kabi AG, Galapagos NV, Gilead Sciences, Inc., GlaxoSmithKline PLC, ILTOO Pharma SAS, Johnson & Johnson Services Inc., medac GmbH, Merck & Co., Inc., Novartis AG, Otter Pharmaceuticals, LLC by Assertio Holdings, Inc., Pfizer, Inc., Regeneron Pharmaceuticals, Inc., Sanofi SA, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., UCB S.A., and Vertex Pharmaceuticals Incorporated. Actionable Recommendations for Strategic Market Leadership

Industry leaders are encouraged to adopt a multifaceted approach to harness the full potential of the anti-rheumatics market. To remain competitive, it is essential to invest in robust R&D capabilities that focus on precision medicine and personalized therapies, ensuring that treatment options are tailored to individual patient needs. Expanding product portfolios across diverse drug classes and routes of administration can effectively address varying patient demographics and preferences. Leaders should also explore strategic partnerships and collaborations to accelerate innovation and expand market access, particularly in emerging economies where healthcare infrastructure is rapidly evolving. An emphasis on data-driven insights will enable decision-makers to identify untapped market segments and optimize distribution channels, including hospital, online, and retail pharmacies. Furthermore, leveraging digital technologies such as AI and machine learning can streamline clinical trials and enhance patient engagement. Regulatory compliance must remain at the forefront of any strategic initiative, with a proactive approach to meet evolving global standards. By embracing these recommendations, companies can not only mitigate market risks but also capitalize on emerging trends, ultimately driving sustainable growth and competitive differentiation in a constantly evolving healthcare landscape.

Conclusion: Synthesizing Insights for Future Growth

In summary, the anti-rheumatics market presents robust opportunities underpinned by transformative technological and regulatory advancements. The in-depth segmentation analysis, regional evaluations, and company performance insights collectively reinforce a narrative of dynamic growth and innovation. As the landscape continues to evolve with a focus on targeted therapies and patient-centric solutions, stakeholders are well-positioned to benefit from these changes by strategically aligning their business models with current market trends. This comprehensive summary encapsulates the critical areas that require focus and continued investment to ensure long-term success in the anti-rheumatics domain.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increase in the prevalence of rheumatic disorders
      • 5.1.1.2. Rise in awareness related to early screening and treatment of rheumatoid arthritis
      • 5.1.1.3. Growing emphasis on precision therapeutics and personalized medicine
    • 5.1.2. Restraints
      • 5.1.2.1. Side effects and safety issues associated with anti-rheumatic drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Government initiatives and support for the research and development of the rheumatic diseases
      • 5.1.3.2. Significant development and marketing of cost-effective biosimilars
    • 5.1.4. Challenges
      • 5.1.4.1. Complex drug development and approval processes
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Drug Class: Increasing adoption of nonsteroidal anti-inflammatory drugs due to their accessibility, affordability, and effective management of pain
    • 5.2.2. Route Of Administration: Advancements in oral drug formulations aiming to improve bioavailability and minimize adverse effects
    • 5.2.3. Type: Significant preference for prescription-based drugs in managing severe and chronic rheumatic diseases
    • 5.2.4. Disease Type: Evolving personalized medicine advancement in rheumatoid arthritis to optimize treatment outcomes and minimize side effects.
    • 5.2.5. Distribution Channel: Expanding online pharmacies for anti-rheumatic medication distribution
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Anti-Rheumatics Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Corticosteroids
  • 6.3. Disease Modifying Anti-rheumatics Drugs
    • 6.3.1. Biologic DMARDs
      • 6.3.1.1. B-cell Inhibitors
      • 6.3.1.2. Interleukin Inhibitors
      • 6.3.1.3. T-cell Co-stimulation Modulators
      • 6.3.1.4. Tumor Necrosis Factor (TNF) Inhibitors
    • 6.3.2. Conventional DMARDs
    • 6.3.3. Targeted Synthetic DMARDs
  • 6.4. Nonsteroidal Anti-inflammatory Drugs
  • 6.5. Uric Acid Drugs

7. Anti-Rheumatics Market, by Route Of Administration

  • 7.1. Introduction
  • 7.2. Injectable
  • 7.3. Oral
  • 7.4. Topical

8. Anti-Rheumatics Market, by Type

  • 8.1. Introduction
  • 8.2. Over-the-Counter Drugs
  • 8.3. Prescription-Based Drugs

9. Anti-Rheumatics Market, by Disease Type

  • 9.1. Introduction
  • 9.2. Ankylosing Spondylitis
  • 9.3. Bursitis
  • 9.4. Gout
  • 9.5. Juvenile Idiopathic Arthritis
  • 9.6. Osteoarthritis
  • 9.7. Osteoporosis
  • 9.8. Polymyalgia Rheumatica
  • 9.9. Psoriatic Arthritis
  • 9.10. Rheumatoid Arthritis
  • 9.11. Sjogren's Syndrome
  • 9.12. Systemic Lupus Erythematosus
  • 9.13. Systemic Sclerosis/Scleroderma
  • 9.14. Tendinitis

10. Anti-Rheumatics Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Hospital Pharmacies
  • 10.3. Online Pharmacies
  • 10.4. Retail Pharmacies

11. Americas Anti-Rheumatics Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Anti-Rheumatics Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Anti-Rheumatics Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Johnson & Johnson showcases advances in rheumatic disease treatments with 43 abstracts at ACR 2024
    • 14.3.2. FDA expands Shorla's JYLAMVO approval to combat pediatric oncology and autoimmune conditions
    • 14.3.3. DeepCure's DC-9476 methotrexate resistance in rheumatoid arthritis treatment
    • 14.3.4. FDA approval of Kevzara for treatment of pediatric and adult inflammatory arthritis
    • 14.3.5. Eisai and nippon medac launch Japan's first self-administered methotrexate pen
    • 14.3.6. Teva and Alvotech introduce SIMLANDI an interchangeable Humira biosimilar in the U.S.
    • 14.3.7. Kiniksa advances abiprubart in Phase 2b Trial for Sjogren's Disease, building on results from rheumatoid arthritis trial
    • 14.3.8. Fresenius Kabi's FDA approval of TYENNE tocilizumab biosimilar introduces in the anti-rheumatics market
    • 14.3.9. FDA approval revolutionizes rheumatic care with Novartis' Cosentyx
    • 14.3.10. Sandoz launches citrate-free high-concentration biosimilar Hyrimoz in the U.S. market
  • 14.4. Strategy Analysis & Recommendation
    • 14.4.1. GlaxoSmithKline PLC
    • 14.4.2. Johnson & Johnson Services Inc.
    • 14.4.3. Novartis AG
    • 14.4.4. AbbVie Inc.

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Alvotech
  • 3. Amgen Inc.
  • 4. ANI Pharmaceuticals, Inc.
  • 5. AstraZeneca PLC
  • 6. Bayer AG
  • 7. Biogen Inc.
  • 8. Bristol-Myers Squibb Company
  • 9. C. H. Boehringer Sohn AG & Co. KG
  • 10. DeepCure
  • 11. Eisai Co., Ltd.
  • 12. Eli Lilly and Company
  • 13. F. Hoffmann-La Roche Ltd.
  • 14. Fresenius Kabi AG
  • 15. Galapagos NV
  • 16. Gilead Sciences, Inc.
  • 17. GlaxoSmithKline PLC
  • 18. ILTOO Pharma SAS
  • 19. Johnson & Johnson Services Inc.
  • 20. medac GmbH
  • 21. Merck & Co., Inc.
  • 22. Novartis AG
  • 23. Otter Pharmaceuticals, LLC by Assertio Holdings, Inc.
  • 24. Pfizer, Inc.
  • 25. Regeneron Pharmaceuticals, Inc.
  • 26. Sanofi SA
  • 27. Takeda Pharmaceutical Company Limited
  • 28. Teva Pharmaceutical Industries Ltd.
  • 29. UCB S.A.
  • 30. Vertex Pharmaceuticals Incorporated

LIST OF FIGURES

  • FIGURE 1. ANTI-RHEUMATICS MARKET MULTI-CURRENCY
  • FIGURE 2. ANTI-RHEUMATICS MARKET MULTI-LANGUAGE
  • FIGURE 3. ANTI-RHEUMATICS MARKET RESEARCH PROCESS
  • FIGURE 4. ANTI-RHEUMATICS MARKET SIZE, 2023 VS 2030
  • FIGURE 5. GLOBAL ANTI-RHEUMATICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 17. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 21. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 25. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 26. ANTI-RHEUMATICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 27. ANTI-RHEUMATICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ANTI-RHEUMATICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ANTI-RHEUMATICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANTI-RHEUMATICS MARKET DYNAMICS
  • TABLE 7. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY B-CELL INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY T-CELL CO-STIMULATION MODULATORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TUMOR NECROSIS FACTOR (TNF) INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY CONVENTIONAL DMARDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TARGETED SYNTHETIC DMARDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY URIC ACID DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY PRESCRIPTION-BASED DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY ANKYLOSING SPONDYLITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY BURSITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY GOUT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY JUVENILE IDIOPATHIC ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY OSTEOARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY OSTEOPOROSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY POLYMYALGIA RHEUMATICA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY PSORIATIC ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY SJOGREN'S SYNDROME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY SYSTEMIC LUPUS ERYTHEMATOSUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY SYSTEMIC SCLEROSIS/SCLERODERMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TENDINITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 49. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 50. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 53. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 54. ARGENTINA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 57. ARGENTINA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 58. ARGENTINA ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. ARGENTINA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. ARGENTINA ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 61. BRAZIL ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 62. BRAZIL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
  • TABLE 63. BRAZIL ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 64. BRAZIL ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 65. BRAZIL ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. BRAZIL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. BRAZIL ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 68. CANADA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 69. CANADA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
  • TABLE 70. CANADA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 71. CANADA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 72. CANADA ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. CANADA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. CANADA ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 75. MEXICO ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 76. MEXICO ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
  • TABLE 77. MEXICO ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 78. MEXICO ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 79. MEXICO ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. MEXICO ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. MEXICO ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 82. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 83. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
  • TABLE 84. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 85. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 86. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 89. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 98. AUSTRALIA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 99. AUSTRALIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
  • TABLE 100. AUSTRALIA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 101. AUSTRALIA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 102. AUSTRALIA ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. AUSTRALIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. AUSTRALIA ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 105. CHINA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 106. CHINA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
  • TABLE 107. CHINA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 108. CHINA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 109. CHINA ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. CHINA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. CHINA ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 112. INDIA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 113. INDIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
  • TABLE 114. INDIA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 115. INDIA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 116. INDIA ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. INDIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. INDIA ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 119. INDONESIA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 120. INDONESIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
  • TABLE 121. INDONESIA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 122. INDONESIA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 123. INDONESIA ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. INDONESIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. INDONESIA ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 126. JAPAN ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 127. JAPAN ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
  • TABLE 128. JAPAN ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 129. JAPAN ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 130. JAPAN ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. JAPAN ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. JAPAN ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 133. MALAYSIA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 134. MALAYSIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
  • TABLE 135. MALAYSIA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 136. MALAYSIA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 137. MALAYSIA ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. MALAYSIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. MALAYSIA ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 140. PHILIPPINES ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 141. PHILIPPINES ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
  • TABLE 142. PHILIPPINES ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 143. PHILIPPINES ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 144. PHILIPPINES ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. PHILIPPINES ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. PHILIPPINES ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 147. SINGAPORE ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 148. SINGAPORE ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
  • TABLE 149. SINGAPORE ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 150. SINGAPORE ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 151. SINGAPORE ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. SINGAPORE ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. SINGAPORE ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 154. SOUTH KOREA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 155. SOUTH KOREA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
  • TABLE 156. SOUTH KOREA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 157. SOUTH KOREA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 158. SOUTH KOREA ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. SOUTH KOREA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. SOUTH KOREA ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 161. TAIWAN ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 162. TAIWAN ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
  • TABLE 163. TAIWAN ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 164. TAIWAN ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 165. TAIWAN ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. TAIWAN ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. TAIWAN ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 168. THAILAND ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 169. THAILAND ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
  • TABLE 170. THAILAND ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 171. THAILAND ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 172. THAILAND ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. THAILAND ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. THAILAND ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 175. VIETNAM ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 176. VIETNAM ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
  • TABLE 177. VIETNAM ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 178. VIETNAM ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 179. VIETNAM ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. VIETNAM ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. VIETNAM ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 190. DENMARK ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 191. DENMARK ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
  • TABLE 192. DENMARK ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 193. DENMARK ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 194. DENMARK ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 195. DENMARK ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. DENMARK ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 197. EGYPT ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 198. EGYPT ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
  • TABLE 199. EGYPT ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 200. EGYPT ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 201. EGYPT ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 202. EGYPT ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 203. EGYPT ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 204. FINLAND ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 205. FINLAND ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
  • TABLE 206. FINLAND ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 207. FINLAND ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 208. FINLAND ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 209. FINLAND ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 210. FINLAND ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 211. FRANCE ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 212. FRANCE ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
  • TABLE 213. FRANCE ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 214. FRANCE ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 215. FRANCE ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 216. FRANCE ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. FRANCE ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 218. GERMANY ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 219. GERMANY ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
  • TABLE 220. GERMANY ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 221. GERMANY ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 222. GERMANY ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 223. GERMANY ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 224. GERMANY ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 225. ISRAEL ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 226. ISRAEL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
  • TABLE 227. ISRAEL ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 228. ISRAEL ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 229. ISRAEL ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 230. ISRAEL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 231. ISRAEL ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 232. ITALY ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 233. ITALY ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
  • TABLE 234. ITALY ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 235. ITALY ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 236. ITALY ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 237. ITALY ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 238. ITALY ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 239. NETHERLANDS ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 240. NETHERLANDS ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
  • TABLE 241. NETHERLANDS ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 242. NETHERLANDS ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 243. NETHERLANDS ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 244. NETHERLANDS ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 245. NETHERLANDS ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 246. NIGERIA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 247. NIGERIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
  • TABLE 248. NIGERIA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 249. NIGERIA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 250. NIGERIA ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 251. NIGERIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 252. NIGERIA ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 253. NORWAY ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 254. NORWAY ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
  • TABLE 255. NORWAY ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 256. NORWAY ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 257. NORWAY ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 258. NORWAY ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 259. NORWAY ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 260. POLAND ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 261. POLAND ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
  • TABLE 262. POLAND ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 263. POLAND ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 264. POLAND ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 265. POLAND ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 266. POLAND ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 267. QATAR ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 268. QATAR ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
  • TABLE 269. QATAR ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 270. QATAR ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 271. QATAR ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 272. QATAR ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 273. QATAR ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 274. RUSSIA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 275. RUSSIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
  • TABLE 276. RUSSIA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 277. RUSSIA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 278. RUSSIA ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 279. RUSSIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 280. RUSSIA ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 281. SAUDI ARABIA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 282. SAUDI ARABIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
  • TABLE 283. SAUDI ARABIA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 284. SAUDI ARABIA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 285. SAUDI ARABIA ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 286. SAUDI ARABIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 287. SAUDI ARABIA ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 288. SOUTH AFRICA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 289. SOUTH AFRICA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
  • TABLE 290. SOUTH AFRICA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 291. SOUTH AFRICA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 292. SOUTH AFRICA ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 293. SOUTH AFRICA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 294. SOUTH AFRICA ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 295. SPAIN ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 296. SPAIN ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
  • TABLE 297. SPAIN ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 298. SPAIN ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 299. SPAIN ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 300. SPAIN ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 301. SPAIN ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 302. SWEDEN ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 303. SWEDEN ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
  • TABLE 304. SWEDEN ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 305. SWEDEN ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 306. SWEDEN ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 307. SWEDEN ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 308. SWEDEN ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 309. SWITZERLAND ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 310. SWITZERLAND ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
  • TABLE 311. SWITZERLAND ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 312. SWITZERLAND ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 313. SWITZERLAND ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 314. SWITZERLAND ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 315. SWITZERLAND ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 316. TURKEY ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 317. TURKEY ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
  • TABLE 318. TURKEY ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 319. TURKEY ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 320. TURKEY ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 321. TURKEY ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 322. TURKEY ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 323. UNITED ARAB EMIRATES ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 324. UNITED ARAB EMIRATES ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
  • TABLE 325. UNITED ARAB EMIRATES ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 326. UNITED ARAB EMIRATES ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 327. UNITED ARAB EMIRATES ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 328. UNITED ARAB EMIRATES ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 329. UNITED ARAB EMIRATES ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 330. UNITED KINGDOM ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 331. UNITED KINGDOM ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
  • TABLE 332. UNITED KINGDOM ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 333. UNITED KINGDOM ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 334. UNITED KINGDOM ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 335. UNITED KINGDOM ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 336. UNITED KINGDOM ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 337. ANTI-RHEUMATICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 338. ANTI-RHEUMATICS MARKET, FPNV POSITIONING MATRIX, 2023